Browse our 650+ Publications​

Latest Publications

Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

Shi Q, et al.
J Clin Oncol
February 2025
Authors and Affiliates
Qian Shi, PhD1 ; Bruno Paiva, PhD2 ; Levi D. Pederson, MS1 ; Natalie Dimier, PhD3; Ela Talpes, PhD4; Thomas J. Prior, PhD5 ; Alberto Orfao, MD, PhD6 ; Philippe Moreau, MD, PhD7 ; Pieter Sonneveld, MD, PhD8 ; Shaji K. Kumar, MD9 ; Jesse G. Dixon, MS1; Reshma Patel, PhD10; Blake J. Bartlett, PhD5; Jordan Schecter, MD5; Phillip McCarthy, MD11 ; Dirk Hose, MD12 ; Anja Seckinger, MD12 ; D’Agostino Mattia, MD13 ; Hartmut Goldschmidt, MD14 ; Stefania Oliva, MD15 ; Roger G. Owen, MD16; Kenneth C. Anderson, MD17 ; Jes´us San-Miguel, MD, PhD18 ; Brian G.M. Durie, MD19; and Nikhil Munshi, MD17 ; on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group 1Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 2Department of Hematology and Immunology, University of Navara, Pamplona, Spain 3Roche Products Limited, St Albans, United Kingdom 4Amgen Inc, San Francisco, CA 5Johnson & Johnson Inc, New Brunswick, NJ 6Department of Medicine, University of Salamanca, Salamanca, Spain 7Hematology Department, University Hospital Hotel-dieu, Nantes, France 8Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands 9Division of Hematology, Mayo Clinic, Rochester, MN 10Johnson & Johnson Inc, High Wycombe, United Kingdom 11Roswell Park Cancer Institute, Buffalo, NY 12Department of Hematology and Immunology, Myeloma Center Brussels & Labor f¨ur Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium 13Division of Hematology, Department of Molecular Biotechnology and Health Sciences, AOU Citt `a della Salute e della Scienza di Torino, University of Torino, Torino, Italy 14University Hospital Heidelberg, GMMG—Study Group at the University Hospital Heidelberg, Heidelberg, Germany 15Myeloma Unit, Division of Hematology, University of Torino, Turin, Italy 16St James Institute, Leeds, United Kingdom 17Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 18Professor of Hematology, Senior Consultant & Strategic Advisor, Clinica Universidad de Navarra, Pamplona, Spain 19Cedars Sinai Outpatient Cancer Center, Los Angeles, CA

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Usmani S, et al.
Nature Medicine
February 2025
Authors and Affiliates
Saad Z. Usmani 1 , Thierry Facon2, Vania Hungria3, Nizar J. Bahlis 4, Christopher P. Venner5,6, Marc Braunstein7, Ludek Pour8, Josep M. Martí9, Supratik Basu 10, Yael C. Cohen 11,12, Morio Matsumoto13, Kenshi Suzuki14, Cyrille Hulin15, Sebastian Grosicki16, Wojciech Legiec17, Meral Beksac18, Angelo Maiolino 19,20, Hiroyuki Takamatsu21, Aurore Perrot 22, Mehmet Turgut23, Tahamtan Ahmadi24, Weiping Liu25, Jianping Wang26, Katherine Chastain27, Jessica Vermeulen28, Maria Krevvata26, Lorena Lopez-Masi27, Jodi Carey26, Melissa Rowe29, Robin Carson26 & Sonja Zweegman30 1Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France. 3Clínica Médica São Germano, São Paulo, Brazil. 4Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada. 5Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. 6BC Cancer—Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada. 7Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. 8University Hospital Brno, Brno, Czech Republic. 9Hospital Universitario Mútua de Terrassa, Terrassa, Spain. 10Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK. 11Department of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel. 12Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. 13Department of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan. 14Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. 15Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France. 16Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland. 17Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland. 18Istinye University, Ankara Liv Hospital, Ankara, Turkey. 19Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil. 20Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 21Department of Hematology, Kanazawa University Hospital, Kanazawa University, Kanazawa, Japan. 22CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France. 23Department of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey. 24Genmab US, Inc., Plainsboro, NJ, USA. 25Johnson & Johnson, Shanghai, China. 26Johnson & Johnson, Spring House, PA, USA. 27Johnson & Johnson, Raritan, NJ, USA. 28Johnson & Johnson, Leiden, The Netherlands. 29Johnson & Johnson, High Wycombe, UK. 30Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy

Costa L, et al.
Blood Cancer Journal
February 2025
Authors and Affiliates
Luciano J. Costa 1✉, Eva Medvedova2, Binod Dhakal 3, Bhagirathbhai R. Dholaria 4, Kelly N. Godby1, Susan Bal1, Gayathri Ravi1, Smith Giri1, Saurabh Chhabra 3,5, Rebecca Silbermann2 and Natalie S. Callander 6 1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. 2Division of Hematology/ Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 3Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 4Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 5Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA. 6University of Wisconsin, Madison, WI, USA.

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Brown J, et al.
nejm
February 2025
Authors and Affiliates
J.R. Brown,1 J.F. Seymour,2,3 W. Jurczak,4 A. Aw,5 M. Wach,6 A. Illes,7 A. Tedeschi,8 C. Owen,9 A. Skarbnik,10 D. Lysak,11 K.-S. Eom,12 M. Šimkovič,13 M.A. Pavlovsky,14 A.P. Kater,15 B. Eichhorst,16 K. Miller,17 V. Munugalavadla,17 T. Yu,17 M. de Borja,18 and P. Ghia,19,20 for the AMPLIFY investigators* 1 Dana–Farber Cancer Institute, Boston; 2 Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; 3 Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia; 4 Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland; 5 University of Ottawa, Ottawa; 6 Medical University of Lublin, Lublin, Poland; 7 Faculty of Medicine, Division of Hematology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary; 8 ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan; 9 University of Calgary, Calgary, AB, Canada; 10 Novant Health Cancer Institute, Charlotte, NC; 11 Fakultní Nemocnice Plzen, Pilsen, Czech Republic; 12 Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, South Korea; 13 4th Department of Internal Medicine–Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University, Hradec Kralove, Czech Republic; 14 FUNDALEU, Clinical Research Center, Buenos Aires; 15 Amsterdam University Medical Centers, University of Amsterdam, Amsterdam; 16 University Hospital Cologne, Cologne, Germany; 17 AstraZeneca, South San Francisco, CA; 18 AstraZeneca, Mississauga, ON, Canada; 19 Università Vita-Salute San Raffaele, Milan; 20 IRCCS Ospedale San Raffaele, Milan.

Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial

Perrot A, et al.
Blood
January 2025
Authors and Affiliates
Aurore Perrot,1 Cyrille Touzeau,2 Jerome Lambert,3 Cyrille Hulin,4 Denis Caillot,5 Lionel Karlin,6 Bertrand Arnulf,7 Philippe Rey,8 Laurent Garderet,9 Margaret Macro,10 Martine Escoffre Barbe,11 Julie Gay,12 Thomas Chalopin,13 Romain Gounot,14 Jean-Marc Schiano,15 Mourad Tiab,16 Mohamad Mohty,17 Frederique Kuhnowski,18 Jean Fontan,19 Salomon Manier,20 Frederique Orsini-Piocelle,21 Laure Vincent,22 Sophie Rigaudeau,23 Xavier Leleu,24 Benjamin Hebraud,1 Laurent Flet,25 Jean-Valere Malfuson,26 Caroline Jacquet,27 Driss Chaoui,28 Nathalie Meuleman,29 Wajed Abarah,30 Lydia Montes,31 Riad Benramdane,32 Cecile Sonntag,33 Hacene Zerazhi,34 Alina Danu,35 Olivier Allangba,36 Mamoun Dib,37 Murielle Roussel,38 Sophie Cereja,39 Julien Depaus,40 Nicolas Branche,41 Helene Demarquette,42 Valentine Richez,43 Brieuc Cherel,44 Laurent Frenzel,45 Marie-Christiane Vekemans,46 Noemie Bigot,3 Herve Avet-Loiseau,47 Jill Corre,47 Philippe Moreau2 1Hematologie, Hopital Universitaire de Toulouse, France 2Hematologie, Hopital Universitaire de Nantes, France 3Biostatistique, Hopital Universitaire Saint Louis, APHP, Paris, France 4Hematologie, Hopital Universitaire de Bordeaux, France 5Hematologie, Hopital Universitaire de Dijon, France 6Hematologie, Hopital Universitaire de Lyon Sud, France 7Hematologie, Hopital Universitaire Saint Louis, APHP, Paris, France 8Hematologie, Centre Léon Bérard, Lyon, France 9Hematologie, Hopital Universitaires Pitié Salpêtrière, APHP, Paris, France 10Hematologie, Hopital Universitaire de Caen, France 11Hematologie, Hopital Universitaire de Rennes, France 12Hematologie, Hopital de Bayonne, France 13Hematologie, Hopital Universitaire de Tours, France 14Hematologie, Hopital Universitaire Henri Mondor, Créteil, France 15Hematologie, Institut Paoli Calmettes, Marseille, France 16Hematologie, Hopital Vendée, La Roche sur Yon, France 17Hematologie, Hopital Universitaire Saint Antoine, APHP, Paris, France 18Hematologie, Institut Curie, Paris, France 19Hematologie, Hopital Universitaire de Besançon, France 20Hematologie, Hopital Universitaire de Lille, France 21Hematologie Hopital d’Annecy, France 22Hematologie, Hopital Universitaire de Montpellier, France 23Hematologie, Hopital de Versailles, France 24Hematologie, Hopital Universitaire de Poitiers, France 25Parmacie, Hopital Universitaire de Nantes, France 26Hematologie, Hopital d’Instruction des Armees, Percy, France 27Hematologie Hopital Universitaire de Nancy, France 28Hematologie, Hopital d’Argenteuil, France 29Hematologie, Institut Jules Bordet, Bruxelles, Belgique 30Hematologie, Grand Hopital de l’Est Francilien, Meaux, France 31Hematologie, Hopital Universitaire d’Amiens, France 32Hematologie Hopital de Cergy-Pontoise, France 33Hematologie, ICANS, Strasbourg, France 34Hematologie, Hopital d’Avignon, France 35Hematologie, Institut Gustave Roussy, Villejuif, France 36Hematologie, Hopital de Saint Brieuc, France 37Hematologie, Hopital Universitaire d’Angers, France 38Hematologie Hopital Universitaire de Limoges, France 39Hematologie, Hopital Sud Francilien, Corbeil Essonnes, France 40Hematologie, Hopital de Namur, Belgium 41Hematologie, Hopital Universitaire de Nîmes, France 42Hematologie, Hopital de Dunkerque, France 43Hematologie, Hopital Universitaire de Nice, France 44Hematologie, Hopital de Vannes, France 45Hematologie, Hopital Universitaire Necker, APHP, Paris, France 46Hematologie, Cliniques Universitaires St Luc, Bruxelles, Belgium 47Unite Genomique du Myelome, Toulouse, France

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study

Moreau P, et al.
Leukemia
January 2025
Authors and Affiliates
Philippe Moreau 1✉, Thierry Facon2, Saad Z. Usmani 3, Nizar Bahlis 4, Noopur Raje5, Torben Plesner6, Robert Z. Orlowski 7, Supratik Basu 8, Hareth Nahi 9, Cyrille Hulin 10, Hang Quach 11, Hartmut Goldschmidt 12, Michael O’Dwyer 13, Aurore Perrot 14, Christopher P. Venner15,16, Katja Weisel 17, Mourad Tiab18, Margaret Macro19, Laurent Frenzel20, Xavier Leleu 21, George Wang22, Huiling Pei23, Maria Krevvata22, Robin Carson22, Fredrik Borgsten24 and Shaji K. Kumar 1Hematology Department, University Hospital Hôtel-Dieu, Nantes, France. 2University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France. 3Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. 5Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, USA. 6Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 7Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, UK. 9Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden. 10Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France. 11University of Melbourne, St Vincent’s Hospital, Melbourne, Australia. 12GMMG-Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany. 13Department of Medicine/Haematology, University of Galway, Galway, Republic of Ireland. 14CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France. 15Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 16Department of Medical Oncology, BC Cancer – Vancouver Centre, University of British Columbia, Vancouver, BC, Canada. 17Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 18CHD Vendée, La Roche sur Yon, France. 19Centre Hospitalier Universitaire (CHU) de Caen, Caen, France. 20Hôpital Necker-Enfants Malades, Paris, France. 21CHU Poitiers, Hôpital la Milétrie, Poitiers, France. 22Janssen Research & Development, LLC, Spring House, PA, USA. 23Janssen Research & Development, LLC, Titusville, NJ, USA. 24Janssen Research & Development, LLC, Raritan, NJ, USA. 25Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.

Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti‑CD38monoclonal antibodies

Costa L, et al.
Annals of Hematology
January 2025
Authors and Affiliates
Luciano J. Costa1 · Francesca Gay2 · Ola Landgren3 · María‑Victoria Mateos4 · Philippe Moreau5 · Cyrille Touzeau5 · Franziska Ertel6 · Ian McFadden7 · Rani Najdi7 · Katja Weisel8 1 Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham Hospital, 1802 6Th Avenue South, Birmingham, AL 35294, USA 2 AOU Città Della Salute E Della Scienza Di Torino, University of Torino, Turin, Italy 3 Division of Myeloma, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA 4 University Hospital Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain 5 The Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France 6 Amgen GmbH, Munich, Germany 7 Amgen Inc, Thousand Oaks, CA, USA 8 Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Hyper-CVADand Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Kantarjian H, et al.
Am J Hematol
January 2025
Authors and Affiliates
Hagop Kantarjian | Nicholas J. Short | Nitin Jain | Fadi G. Haddad | Tapan Kadia | Musa Yilmaz | Alessandra Ferrajoli | Koji Sasaki | Yesid Alvarado | Naveen Pemmaraju | Jayastu Senapati | Rebecca Garris | Farhad Ravandi | Elias Jabbour Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nadeem O, et al.
Nature Communications
January 2025
Authors and Affiliates
Omar Nadeem1,2,8 , Michelle P. Aranha 1,2,3,8, Robert Redd 4, Michael Timonian 1,2,3, Sophie Magidson 1, Elizabeth D. Lightbody1,2,3, Jean-Baptiste Alberge 1,2,3, Luca Bertamini1,2,3, Ankit K. Dutta1,2,3, Habib El-Khoury1,2,3, Mark Bustoros 1,5, Jacob P. Laubach1, Giada Bianchi6, Elizabeth O’Donnell1, TingWu3, Junko Tsuji3, Kenneth C. Anderson 1, Gad Getz2,3,7, Lorenzo Trippa4, Paul G. Richardson1, Romanos Sklavenitis-Pistofidis1,2,3 & Irene M. Ghobrial 1,2,3 1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2Harvard Medical School, Boston,MA,USA. 3Broad Institute ofMIT andHarvard,Boston,MA,USA. 4Department of Biostatistics andComputational Biology,Dana-Farber Cancer Institute, Boston, MA, USA. 5Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, NY, USA. 6Amyloidosis Program, Division of Hematology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston,MA, USA. 7Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. 8These authors contributed equally: Omar Nadeem, Michelle P. Aranha.

A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease

Davids M, et al.
Journal of Clinical Oncology
December 2024
Authors and Affiliates
Matthew S. Davids, M.D., M.M.Sc.1, Christine E. Ryan, M.D.1, Benjamin L. Lampson, M.D., Ph.D.1, Yue Ren, M.S.2, Svitlana Tyekucheva, Ph.D.2, Stacey M. Fernandes, B.S.1, Jennifer L. Crombie, M.D.1, Austin I. Kim, M.D.1, Matthew Weinstock, M.D.3, Josie Montegaard, N.P.1, Heather A. Walker, M.P.H.1, Claire Greenman, B.A.,1 Victoria Patterson, R.N.1, Caron A. Jacobson, M.D., M.M.Sc.1, Ann S. LaCasce, M.D., M.M.Sc.1, Philippe Armand, M.D., Ph.D.1, David C. Fisher, M.D.1, Steve Lo, M.D.,4 Adam J. Olszewski, M.D.,5 Jon E. Arnason, M.D.3, Inhye E. Ahn, M.D.1, Jennifer R. Brown, M.D., Ph.D.1 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA 3Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA 4Stamford Hospital, Stamford, CT, USA 5Brown University Health, Providence, RI, USA
Previous Next